CAW
SAGE

Cornerstone Advisors (Washington)’s Sage Therapeutics SAGE Stock Holding History

Cornerstone Advisors (Washington)’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-340
Closed -$62K – 1260
2019
Q2 		$62K Buy
340
+32
+10% +$5.46K 0.01% 343
2019
Q1 		$49K Buy
308
+68
+28% +$9.85K ﹤0.01% 367
2018
Q4 		$23K Hold
240
– – ﹤0.01% 482
2018
Q3 		$34K Hold
240
– – 0.02% 419
2018
Q2 		$38K Buy
+240
New +$37.7K 0.03% 363

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Cornerstone Advisors (Washington)'s SAGE Position: Q3 2019 in Review

Cornerstone Advisors (Washington) sold out of Sage Therapeutics (SAGE) in Q3 2019, closing a stake of 340 shares — an estimated $62K sold.

Cornerstone Advisors (Washington) first reported a position in SAGE in Q2 2018 and held it in 5 quarters. The position peaked at $62K in Q2 2019. 285 funds tracked by Wall St. Rank hold SAGE as of Q3 2019.

  • Cornerstone Advisors (Washington) reported no remaining Sage Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Cornerstone Advisors (Washington) sold 340 Sage Therapeutics shares in Q3 2019, an estimated $62K.
  • Cornerstone Advisors (Washington) first reported a position in Sage Therapeutics in Q2 2018 and held it in 5 quarters.
  • Cornerstone Advisors (Washington)'s Sage Therapeutics position peaked at $62K in Q2 2019.
  • 285 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2019.

Based on Cornerstone Advisors (Washington)'s 13F filing for Q3 2019, filed 23 Oct 2019.